Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease (NCT07317297) | Clinical Trial Compass
RecruitingNot Applicable
Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease
Azerbaijan50 participantsStarted 2026-01-10
Plain-language summary
Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.
Who can participate
Age range18 Years – 65 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male individuals aged 18-65 years.
* Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.
* Presence of palpable penile plaque.
Exclusion Criteria:
* Acute inflammatory stage (painful, progressive)
* Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.
* Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.
* History of penile cancer.
* Severe erectile dysfunction.
* Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.